Last reviewed · How we verify
NCT06234852
Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus.
NA trial testing Glucocorticoid withdrawal group in Systemic Lupus Erythematosus, SLE in 20 participants. Completed in 17 April 2024.
26 December 2023
Quick facts
| Lead sponsor | Phramongkutklao College of Medicine and Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 24 January 2023 |
| Primary completion | 26 December 2023 |
| Estimated completion | 17 April 2024 |
| Sites | 1 location across Thailand |
Drugs / interventions tested
- Glucocorticoid withdrawal group
- Glucocorticoid maintenance group
Conditions studied
- Systemic Lupus Erythematosus, SLE — all drugs for Systemic Lupus Erythematosus, SLE →
Sponsor
Phramongkutklao College of Medicine and Hospital
Who can join
20 and older, any sex, with Systemic Lupus Erythematosus, SLE. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims compare the flare rate of maintenance versus gradual withdrawal of 5 mg/day prednisone in systemic lupus erythematosus (SLE) patients with clinically quiescent disease.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Effect of Gradual Withdrawal Versus Maintenance of Low-Dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus, a Pilot Double-Blind Randomised Controlled Trial.
Niyompanichakarn S, Chaiamnuay S, Narongroeknawin P, Asavatanabodee P, et al · · 2025 · PMID 40148251 · DOI 10.1002/msc.70083
Verify or expand the search:
- PubMed search for NCT06234852
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Systemic Lupus Erythematosus, SLE
Currently open trials in the same condition.
- NCT06335979 — An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE). · Phase 1 · recruiting
- NCT05688696 — Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus · Phase 2 · recruiting
Other Phramongkutklao College of Medicine and Hospital trials
Trials by the same sponsor.
- NCT07366450 — High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma · NA · not yet recruiting
- NCT07014371 — Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA) · NA · recruiting
- NCT06491342 — Probiotic Supplement Versus Placebo for the Treatment of Patients With Non-alcoholic Fatty Liver Disease · NA · completed
- NCT06279507 — Efficacy of Hyaluronic Acid Injection in Knee Osteoarthritis · Phase 4 · unknown
- NCT06049771 — The Population Pharmacokinetics Study of Tigecycline and Pharmacokinetics- Pharmacodynamics Index in Patients With Carba · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06234852 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Phramongkutklao College of Medicine and Hospital
- Last refreshed: 19 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06234852.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing